

GALECTIN THERAPEUTICS INC

Form 8-K

November 22, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**November 18, 2011**

**Date of Report (Date of earliest event reported)**

**GALECTIN THERAPEUTICS INC.**

**(Exact name of registrant as specified in its charter)**

Edgar Filing: GALECTIN THERAPEUTICS INC - Form 8-K

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)  
7 WELLS AVENUE

(IRS Employer  
Identification No.)

NEWTON, MASSACHUSETTS

02459

(Address of principal executive offices) (Zip Code)

(617) 559-0033

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

In the Form 10-Q Quarterly Report that Galectin Therapeutics Inc. filed on November 10, 2011, we reported that a dispute arose after the settlement agreement was executed with Custom Equity Research, Incorporated (d/b/a Summer Street Research Partners). Following a hearing, the court enforced the settlement agreement upon the terms and for the amount the parties originally negotiated, and both the lawsuit and FINRA arbitration were dismissed with prejudice on November 18, 2011.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Galectin Therapeutics Inc.

By: /s/ Anthony D. Squeglia  
Anthony D. Squeglia  
Chief Financial Officer

Date: November 22, 2011